Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
DVAX

DVAX - Dynavax Technologies Corp Stock Price, Fair Value and News

11.57USD-0.44 (-3.66%)Market Closed

Market Summary

DVAX
USD11.57-0.44
Market Closed
-3.66%

DVAX Alerts

  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

DVAX Stock Price

View Fullscreen

DVAX RSI Chart

DVAX Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

164.22

Price/Sales (Trailing)

6.41

EV/EBITDA

72.65

Price/Free Cashflow

28.74

DVAX Price/Sales (Trailing)

DVAX Profitability

EBT Margin

3.33%

Return on Equity

1.49%

Return on Assets

0.93%

Free Cashflow Yield

3.48%

DVAX Fundamentals

DVAX Revenue

Revenue (TTM)

236.1M

Rev. Growth (Yr)

8.24%

Rev. Growth (Qtr)

-8.64%

DVAX Earnings

Earnings (TTM)

9.2M

Earnings Growth (Yr)

64.16%

Earnings Growth (Qtr)

-4.1K%

Breaking Down DVAX Revenue

Last 7 days

-4.1%

Last 30 days

4.8%

Last 90 days

-4.0%

Trailing 12 Months

-10.7%

How does DVAX drawdown profile look like?

DVAX Financial Health

Current Ratio

15.2

DVAX Investor Care

Shares Dilution (1Y)

1.87%

Diluted EPS (TTM)

0.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024236.1M000
2023655.6M459.4M361.2M232.3M
2022470.1M673.8M733.3M722.7M
2021119.0M169.1M263.9M439.4M
202040.4M34.7M37.6M46.6M
201913.8M20.9M30.0M35.2M
2018344.0K1.5M2.9M8.2M
20178.4M5.7M3.0M327.0K
20164.4M5.5M4.4M11.0M
20158.2M6.7M5.6M4.0M
201412.7M12.3M11.6M11.0M
201310.1M10.5M10.9M11.3M
20120009.7M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Dynavax Technologies Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 31, 2024
cano francis
sold
-43,126
11.93
-3,615
-
May 24, 2024
cano francis
acquired
44,250
5.9
7,500
-
May 24, 2024
cano francis
sold (taxes)
-44,250
11.39
-3,885
-
May 23, 2024
paradiso peter r.
acquired
-
-
5,357
-
May 23, 2024
sun elaine d
acquired
-
-
5,357
-
May 23, 2024
macgregor brent
acquired
-
-
5,357
-
May 23, 2024
phillips peggy v
acquired
-
-
5,357
-
May 23, 2024
eastland julia marie
acquired
-
-
5,357
-
May 23, 2024
myers scott dunseth
acquired
-
-
5,357
-
May 23, 2024
kisner daniel l
acquired
-
-
5,357
-

1–10 of 50

Which funds bought or sold DVAX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
new
-
3,502
3,502
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
-4,000
28,000
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-60,000
474,000
-%
May 28, 2024
Boston Partners
new
-
291,720
291,720
-%
May 22, 2024
BURNEY CO/
reduced
-25.27
-2,520,670
4,968,020
0.19%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
67.82
102,479
311,479
0.04%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-9.3
-370,798
1,532,520
-%
May 16, 2024
Tidal Investments LLC
new
-
417,137
417,137
0.01%
May 16, 2024
HANCOCK WHITNEY CORP
reduced
-1.91
-41,725
281,049
0.01%
May 16, 2024
COMERICA BANK
reduced
-13.45
-172,641
572,498
-%

1–10 of 39

Are Funds Buying or Selling DVAX?

Are funds buying DVAX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own DVAX
No. of Funds

Unveiling Dynavax Technologies Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
deep track capital, lp
5.49%
7,093,214
SC 13G/A
Feb 13, 2024
vanguard group inc
7.18%
9,275,788
SC 13G/A
Jan 25, 2024
state street corp
7.35%
9,495,785
SC 13G/A
Jan 19, 2024
blackrock inc.
18.1%
23,396,930
SC 13G/A
Jan 18, 2024
federated hermes, inc.
8.79%
11,364,666
SC 13G/A
May 19, 2023
deep track capital, lp
5.10%
6,556,180
SC 13G
Feb 09, 2023
state street corp
7.83%
9,992,504
SC 13G/A
Feb 09, 2023
vanguard group inc
6.54%
8,344,862
SC 13G
Feb 01, 2023
federated hermes, inc.
9.91%
12,640,363
SC 13G/A
Jan 26, 2023
blackrock inc.
15.0%
19,086,463
SC 13G/A

Recent SEC filings of Dynavax Technologies Corp

View All Filings
Date Filed Form Type Document
Jun 03, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 28, 2024
4
Insider Trading
May 24, 2024
8-K
Current Report

Peers (Alternatives to Dynavax Technologies Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.3B
85.6B
-4.67% -11.11%
9.1
4.09
5.68% 202.39%
327.9B
61.4B
-1.72% 18.35%
142.2
5.34
6.11% -82.30%
160.2B
29.5B
-6.40% 30.72%
42.57
5.42
12.76% -52.47%
156.0B
35.0B
-4.48% -30.74%
134.25
4.45
-26.40% -92.03%
81.1B
27.4B
-2.90% -17.63%
167.32
2.95
1.51% -91.32%
19.3B
16.0B
2.21% 126.25%
-38.95
1.2
7.23% 71.10%
MID-CAP
4.1B
1.7B
1.49% -23.27%
9.54
2.4
54.01% 364.56%
3.7B
4.6B
-11.15% -22.04%
-475.35
0.8
-0.06% 94.55%
2.3B
9.0B
-10.73% -15.05%
-5.09
0.26
10.01% -27.45%
2.0B
676.2M
-4.67% -22.53%
12.79
2.93
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-18.36% 4.97%
-3.72
1.76
24.65% 80.36%
23.5M
1.3M
-2.39% -46.88%
-3.18
18.07
-98.14% -104.71%
18.0M
89.6M
-7.83% -14.52%
-1.27
0.19
287.27% -129.41%
2.4M
21.5M
-7.89% -89.23%
-0.31
0.11
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Dynavax Technologies Corp News

Latest updates
MarketBeat28 hours ago
Investing.com03 Jun 202407:00 am

Dynavax Technologies Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-8.6%51.0056.0070.0060.0047.0018416825611419510853.0083.0020.0013.003.0011.0011.0011.008.006.00
Costs and Expenses7.0%69.0064.0064.0064.0077.0012110612883.0011492.0044.0055.0031.0027.0026.0030.0038.0041.0047.0044.00
Operating Expenses--------------------47.0044.00
  S&GA Expenses6.7%44.0041.0038.0037.0037.0031.0032.0036.0032.0029.0027.0022.0022.0018.0022.0019.0021.0020.0018.0018.0018.00
  R&D Expenses-4.2%14.0014.0014.0013.0014.0013.0013.0010.0011.0011.006.007.008.0010.009.006.005.0012.0013.0016.0021.00
EBITDA Margin179.8%0.08*0.03*0.20*0.27*0.38*0.42*0.46*0.36*0.26*0.21*-0.21*-0.32*---------
Interest Expenses0.2%2.002.002.002.002.002.002.002.002.002.002.003.005.005.005.005.005.005.005.005.003.00
Income Taxes-457.7%-2.781.00-0.101.001.000.000.001.00-1.00-----------
Earnings Before Taxes-1254.3%-11.501.0014.004.00-23.7268.0064.0012933.00101-28.434.00---------
EBT Margin276.9%0.03*-0.02*0.17*0.25*0.36*0.41*0.45*0.35*0.23*0.18*-0.29*-0.45*---------
Net Income-4082.2%-8.720.0014.003.00-24.3368.0064.0012933.00100-28.434.001.00-15.474.00-51.58-12.59-36.76-33.46-42.71-39.67
Net Income Margin242.0%0.04*-0.03*0.17*0.24*0.36*0.41*0.44*0.35*0.23*0.17*-0.15*-0.03*---------
Free Cashflow-244.7%-17.4312.0031.0027.0026.0033.0060.0014.00-51.8011763.00110---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.1%9879979739369709869991,0231,0091,039920648490353353329259279301267297
  Current Assets-0.9%851859836797830917933955941973853584428290290265194209229191223
    Cash Equivalents-12.1%13215015522717420219924917943624613079.0032.0033.0060.0038.0040.0037.0034.00112
  Inventory16.0%62.0053.0049.0053.0058.0059.0010374.0079.0061.0067.0086.0069.0064.0059.0054.0048.0041.0039.0037.0028.00
  Net PPE-2.4%36.0037.0036.0037.0038.0038.0035.0036.0036.0035.0034.0033.0031.0031.0030.0030.0031.0032.0031.0034.0025.00
  Goodwill-2.2%2.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.002.00
Liabilities-1.9%368375368359406405499600721817852565390295284271247271262256253
  Current Liabilities-10.0%56.0062.0054.0045.0092.0015024434546655652920510977.0067.0053.0029.0053.0046.0045.0042.00
  Long Term Debt-----------220220180180180180180179178177176
    LT Debt, Non Current-----------220220180180180180180179178177176
Shareholder's Equity-0.6%61862260557756458150142328722268.0083.0010059.0069.0058.0012.008.0039.0011.0043.00
  Retained Earnings-0.9%-939-930-930-945-948-924-991-1,055-1,184-1,217-1,317-1,288-1,293-1,294-1,278-1,283-1,231-1,218-1,182-1,148-1,105
  Additional Paid-In Capital0.5%1,5621,5551,5421,5281,5161,5111,5021,4851,4761,4421,3861,3731,3941,3521,3491,3431,2461,2291,2241,1611,151
Shares Outstanding1.0%131130129129128128126126125116117113---------
Float----900---1,100---1,000---884---207-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-221.2%-16,67913,76631,12928,04627,62234,94861,56016,651-50,443120,49766,211110,78838,032-15,743-27,821-21,821-26,866-23,012-21,977-36,361-39,902
  Share Based Compensation15.1%13,01411,30910,68710,56210,0348,7278,6137,9297,6466,1625,3765,0244,7233,5164,1024,0881,7785,1894,7489,3496,170
Cashflow From Investing114.0%2,831-20,242-106,07424,722-52,334-32,967-119,04752,502-216,48354,93845,672-63,752-22,63314,342-2,054-49,38310,56324,851-40,219-42,02714,613
Cashflow From Financing-336.7%-4,2031,7762,994-294-3,0901538,0571,02810,28714,8165,3223,33532,30366.001,41293,48214,539-65,74434588,262
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

DVAX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 50,790$ 46,925
Operating expenses:  
Cost of sales - product10,96614,712
Research and development13,52813,605
Selling, general and administrative44,06536,543
Bad debt expense012,313
Total operating expenses68,55977,173
(Loss) income from operations(17,769)(30,248)
Other income (expense):  
Interest income9,4686,597
Interest expense(1,695)(1,686)
Sublease (expense) income (Note 5)(1,602)1,598
Other10123
Net loss before income taxes(11,497)(23,716)
Benefit from (provision for) income taxes2,776(616)
Net loss$ (8,721)$ (24,332)
Net income per share attributable to common stockholders  
Basic$ (0.07)$ (0.19)
Diluted$ (0.07)$ (0.19)
Weighted-average shares used in computing net income per share attributable to common stockholders:  
Basic130,200127,921
Diluted130,200127,921
Product  
Revenues:  
Total revenues$ 47,845$ 43,451
Other Revenue  
Revenues:  
Total revenues$ 2,945$ 3,474

DVAX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 132,033$ 150,279
Marketable securities available-for-sale591,505592,023
Accounts receivaAccounts receivables, net of allowance for doubtful accounts of $12,313 and $0 at March 31, 2024 and December 31, 2023, respectively.44,16140,607
Other receivables1,9933,926
Inventories, net61,80653,290
Prepaid expenses and other current assets19,78818,995
Total current assets851,286859,120
Property and equipment, net36,41337,297
Operating lease right-of-use assets23,39224,287
Goodwill2,0222,067
Other assets73,45274,325
Total assets986,565997,096
Current liabilities:  
Accounts payable2,4315,245
Accrued research and development3,1372,982
Accrued liabilities45,84149,448
Other current liabilities4,5934,520
current liabilities56,00262,195
Convertible Notes, net of debt discount of $2,516 and $2,802 at March 31, 2024 and December 31, 2023, respectively (Note 7)222,984222,698
Long-term portion of lease liabilities28,55929,720
CEPI accrual long-term60,33760,337
Other long-term liabilities20374
Total liabilities368,085375,024
Commitments and contingencies (Note 5)
Stockholders’ equity:  
Common stock: $0.001 par value; 278,000 shares authorized at March 31, 2023 and December 31, 2022; 128,472 shares and 127,604 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively131130
Preferred stock: $0.001 par value; 5,000 shares authorized at March 31, 2023 and December 31, 2022; zero shares outstanding at March 31, 2023 and December 31, 2022, respectively00
Additional paid-in capital1,562,0271,554,634
Accumulated other comprehensive (loss) gain(4,373)(2,108)
Accumulated deficit(939,305)(930,584)
Total stockholders’ equity618,480622,072
Total liabilities and stockholders’ equity$ 986,565$ 997,096
DVAX
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
 CEO
 WEBSITEdynavax.com
 INDUSTRYPharmaceuticals
 EMPLOYEES351

Dynavax Technologies Corp Frequently Asked Questions


What is the ticker symbol for Dynavax Technologies Corp? What does DVAX stand for in stocks?

DVAX is the stock ticker symbol of Dynavax Technologies Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dynavax Technologies Corp (DVAX)?

As of Fri Jun 14 2024, market cap of Dynavax Technologies Corp is 1.51 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DVAX stock?

You can check DVAX's fair value in chart for subscribers.

What is the fair value of DVAX stock?

You can check DVAX's fair value in chart for subscribers. The fair value of Dynavax Technologies Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Dynavax Technologies Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DVAX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Dynavax Technologies Corp a good stock to buy?

The fair value guage provides a quick view whether DVAX is over valued or under valued. Whether Dynavax Technologies Corp is cheap or expensive depends on the assumptions which impact Dynavax Technologies Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DVAX.

What is Dynavax Technologies Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, DVAX's PE ratio (Price to Earnings) is 164.22 and Price to Sales (PS) ratio is 6.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DVAX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Dynavax Technologies Corp's stock?

In the past 10 years, Dynavax Technologies Corp has provided -0.031 (multiply by 100 for percentage) rate of return.